Literature DB >> 24145894

Dyslipidaemia: RNAi targeting PCSK9 decreases lipid levels in a human trial.

Megan Cully.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24145894     DOI： 10.1038/nrcardio.2013.163

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Authors:  Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321
  1 in total
  2 in total

Review 1.  Targeting PCSK9 for therapeutic gains.

Authors:  Michael D Shapiro; Sergio Fazio; Hagai Tavori
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

2.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Senkottuvelan Kadirvel; Chunli Yu; John D Phillips; Maria I New; Abigail Liebow; Kevin Fitzgerald; William Querbes; Robert J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.